Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02139826Phase 1Completed

Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men

Role: lead

NCT02232425Phase 2Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

Role: lead

NCT03055806Phase 2Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)

Role: lead

NCT02962531Phase 1Completed

Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males

Role: lead

NCT02792647Phase 1Completed

A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects

Role: lead

NCT01994083Phase 1Completed

A Study of Multiple Oral Doses of IX-01 in Healthy Men

Role: lead

All 6 trials loaded